• Pricing strategy: Annual January price hikes were deferred due to GST benefits on material costs, with near-term revenue supported by patient volume growth and a higher-realization mix rather than price increases.
• Network expansion: Metropolis plans to add 200–250 collection centers per quarter (600–700 this year), aiming to increase its lab-to-collection center ratio from 1:24 to 1:30 over the next 1.5 years.
• Core Diagnostics profitability: After lifting the acquired business to a high single-digit EBITDA margin and closing 7–8 redundant labs, management expects Core Diagnostics to reach company-level margins by the third year through procurement and operational synergies.
• Specialized testing and genomics: Specialized tests contribute 40% of total revenue and are expanding at 17–18% year-on-year, with new genomics centers in Gurugram and Mumbai driving future specialty portfolio growth.
• Medium-term financial guidance: The company targets a 14–15% revenue CAGR over the next 2–3 years, along with a 125–150 bps EBITDA margin expansion this year toward a 27–28% EBITDA margin target over the next two years.